天津中医药2017，Vol.34Issue(2)：76-81,6.DOI:10.11656/j.issn.1672-1519.2017.02.03
hiPSC-CM在中药早期心脏毒性筛选和上市后安全性再评价中的应用展望
Application potentials of hiPSC-derived cardiomyocytes in preclinical cardiotoxicity screening and post-marketing safety reevaluation of Chinese medicine
摘要
Abstract
Cardiotoxicity is one of the leading causes for drug failure. Compared with the western medicine, cardiotoxicity assessment of traditional Chinese medicine (TCM),which is composed of two or more ingredients, faces greater challenges. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) is equivalent to immature myocardial cells and can proliferate with impunity. It will bring revolutionary change to biomedicine. Based on database of PubMed and CNKI, this review aims to outline the recent progress made in high throughput screening assays for cardiotoxicity assessment and to discuss the potential applications of hiPSC-CM in innovative TCM drug discovery and safety reevaluation of TCM in market.关键词
诱导型人多能干细胞/心肌细胞/心脏毒性/高通量筛选/中药安全性评价Key words
hiPSC/cardiomyocyte/cardiotoxicity/high throughput screen/traditional Chinese medicine safety分类
医药卫生引用本文复制引用
陈晓南,朱彦..hiPSC-CM在中药早期心脏毒性筛选和上市后安全性再评价中的应用展望[J].天津中医药,2017,34(2):76-81,6.基金项目
天津市高等学校创新团队（TD2-5031），国家重大新药创制（2013ZX 09201020），稳心颗粒国际合作项目（2013DFA31620）。 （）
